Humana said it intends to reaffirm its full-year 2024 guidance of approximately $13.93 in diluted earnings per common share (EPS) or approximately $16.00 in adjusted earnings per common share (Adjusted EPS), for the year ending December 31, 2024.

8-KRegulation FD DisclosureFiled Jun 3, 2024Period of report Jun 3, 2024Summary published (UTC) Oct 30, 2026

Key points

AI summary

Humana said it intends to reaffirm its full-year 2024 guidance of approximately $13.93 in diluted earnings per common share (EPS) or approximately $16.00 in adjusted earnings per common share (Adjusted EPS), for the year ending December 31, 2024.
The company said its senior management team is scheduled to meet with investors and analysts from June 3, 2024 to June 28 and intends to reaffirm its guidance during these meetings.
The company said the reaffirmed guidance is consistent with the outlook it issued in its press release dated April 24, 2024.
The company presented the following adjustments from FY 2024 GAAP EPS of approximately $13.93 to Adjusted EPS of approximately $16.00: put/call valuation adjustments of 1.08, amortization of identifiable intangibles of 0.49, impact of exit of employer group commercial medical products business of 0.90, value creation initiatives of 0.24, and cumulative net tax impact of non-GAAP adjustments of (0.64).

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Reaffirms 2024 Full-Year EPS Guidance

Humana said it intends to reaffirm its full-year 2024 guidance of approximately $13.93 in diluted earnings per common share (EPS) or approximately $16.00 in adjusted earnings per common share (Adjusted EPS), for the year ending December 31, 2024.

Source · Based on the filing body and exhibits

Investor and Analyst Meeting Schedule

The company said its senior management team is scheduled to meet with investors and analysts from June 3, 2024 to June 28 and intends to reaffirm its guidance during these meetings.

Source · Based on the filing body and exhibits

Consistency With Prior Guidance

The company said the reaffirmed guidance is consistent with the outlook it issued in its press release dated April 24, 2024.

Source · Based on the filing body and exhibits

Adjustments Between GAAP EPS and Adjusted EPS

The company presented the following adjustments from FY 2024 GAAP EPS of approximately $13.93 to Adjusted EPS of approximately $16.00: put/call valuation adjustments of 1.08, amortization of identifiable intangibles of 0.49, impact of exit of employer group commercial medical products business of 0.90, value creation initiatives of 0.24, and cumulative net tax impact of non-GAAP adjustments of (0.64).

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.